The discovery of a specific high-affinity growth hormone (GH) binding protein (GH-BP) in plasma adds complexity to the dynamics of GH secretion and clearance. Intuitive predictions are that such a protein would damp sharp oscillations in GH concentrations otherwise caused by bursts ofGH secretion into the blood volume, prolong the apparent half-life of circulating GH, and contribute a reservoir function. To test these implicit considerations, we formulated an explicit mathematical model of pulsatile GH secretion and clearance in the presence or absence of a specific high-affinity GH-BP. Simulation experiments revealed that the pulsatile mode of physiological GH secretion creates a highly dynamic (nonequilibrium) system, in which the half-life of free GH, its instantaneous secretion rate, and the GH-BP affinity and capacity all contribute to defining momentary levels of free, bound, and total GH; the percentage of GH bound to protein; and the percentage occupancy of GH-BP. In contrast, the amount of free GH at equilibrium is specified only by the GH distribution volume and secretion rate and the half-life of free hormone. We conclude that the in vivo dynamics ofGH secretion, trapping, and clearance from the circulation offer a variety of regulatory loci at which the time structure of free, bound, and total GH delivery to target tissues can be controlled physiologically. (J. Clin. Invest. 1993. 91:629-641.)
Introduction
Recently a high-affinity, specific, low-capacity growth hormone-binding protein (GH-BP)' that circulates in blood has been characterized, purified, and cloned in humans and several animal species (1) (2) (3) (4) (5) (6) (7) . This high-affinity GH-BP corresponds to the extracellular domain of the tissue growth hormone (GH) receptor (5) (6) (7) (8) (9) , and contrasts with an incompletely character-ized low-affinity binding protein that is unrelated to the GH receptor (10, 11) . High-affinity GH-BP concentrations are very low or dysfunctional in Laron-type dwarfism ( 12, 13) and decreased in fetal plasma and in certain GH-resistant populations such as pygmies in Africa or the New Guinea highlands ( 10, (14) (15) (16) . Studies in heterologous species (e.g., injection of human GH-BP complexed with human GH into the rat) indicate that the presence of a high-affinity binding protein (BP) can prolong the apparent half-life of GH in plasma (17) (18) (19) . Moreover, an intuitive prediction is that plasma GH-BP would damp oscillations engendered by the burstlike secretion ofGH into the plasma compartment, and contribute to the retention of GH in the circulation ( 17, 20, 21 ) . Here, we have tested these intuitive inferences by formulating an explicit mathematical model to evaluate the predicted effects of the high-affinity GH-BP in plasma on the half-life oftotal, bound, and free GH, and the steady-state and nonequilibrium plasma concentrations of free, bound, and total GH as a function of the mode (pulsatile vs. continuous) and amount of GH secreted.
Methods
Computer simulations ofGH dynamics in vivo. As an initial approximation of the dynamics of GH secretion and removal in the absence and presence of a GH-BP, we assumed that a single high-affinity, lowcapacity, and specific GH-BP contributes predominantly to GH binding in plasma, i.e., that any contribution of other low-affinity BPs is relatively small by comparison, as has been shown (10, 11, 22) . In addition, we provisionally assumed that (a) the turnover ofthe GH-BP is slow compared to that of free GH itself; (b) the intact GH-BP complex is removed at a rate that is slow compared to the clearance of free GH ( 18) ; (c) GH and BP mass are conserved; (d) the binding stoichiometry of GH to its BP is equimolar2; (e) the native elimination function for removal ofGH irreversibly from plasma is a single exponential, which acts only on free GH; (f) GH of 22,000-D molecular mass is measured and constitutes the principal circulating form of GH (23, 24) ; (g) both bound and free GH are measured as immunoreactive GH (25) ; (h) GH is secreted in distinct pulses offinite half-duration (duration at half-maximal amplitude), amplitude, and mass; (i) BP concentration/activity is constant over time (26, 27) ; and (j) the fate of a molecule ofGH injected into the bloodstream by the anterior pituitary gland includes entry into the free (protein unbound) compartment, possible association with the BP, dissociation from the BP, and/or irreversible elimination of free hormone by metabolic and excretory mechanisms.
2. Recent in vitro studies indicate that a single molecule of GH can capture two molecules of recombinant GH-BP through two binding Based on earlier in vitro measurements of the equilibrium association of human GH with its natural high-affinity plasma BP and values averaged from several laboratories ( 1, 2, 9, 12, 20) , we used an apparent equilibrium Kd of 1.5 mM as a nominal value in most simulations. 3 In addition, we used a nominal V0 for GH of 7% body weight (28) , a putative tl/2 oftotal GH of 18 min (29) , and a mean GH-BP concentration of 1.0 nM ( 1, 2, 9) . From earlier estimates, we assumed that the daily total secretion of GH in humans can span an approximate range of0.1 1-1.1 mg/d (5-50 nmol/d), and that a single GH secretory burst has a mass either 2.2 or 22 gg (0.1 or 1.0 pmol), unless indicated otherwise (30) (31) (32) (33) .
The association ofGH with its BP has been previously reported ( 1); its rapidity precludes precise estimation ofthe association rate constant (k/.) with available technology. Therefore, the much slower dissociation ofthe complex was measured. To estimate the unidirectional dissociation rate constant (off rate, koff) of GH from the high-affinity GH-BP, pooled adult human serum (9 ml) was preincubated with -9 ng of monomeric [12251]-human GH for 2 h at 370C as described (1) . An excess of unlabeled human GH (1 mg/liter) was then added in 0.1 ml of phosphate-buffered saline, pH 7.4, and incubation continued at 370C. Periodically, aliquots were removed, immediately chilled in an ice-water bath, and free GH was separated from bound GH on Sephadex G-100 columns at 4VC. Peaks corresponding to the high affinity GH-BP complex and free GH were integrated (1), and bound GH expressed as a function of time after initiation of dissociation. A single rate constant of dissociation was estimated from these measurements as 0.037/min (67% confidence interval 0.030-0.043); see Fig. 1 . (Attempts to determine the dissociation of the low affinity GH-BP complex [ 10] in whole plasma were unsuccessful owing to the small percentage of GH bound to that BP, which rendered precise kinetic estimations difficult.)
The following differential equations were formulated to describe the binding, dissociation, and removal of secreted GH from human plasma. Specifically, given a constant secretion rate, the rates ofchange of concentrations of free and bound GH over time (t) The above differential equations were solved using the RungeKutta formulas as implemented for first-order differential equations (34).
Results
Equilibrium conditions. As a first approximation, we investigated GH kinetics under equilibrium conditions, although under physiological circumstances such conditions rarely apply. As shown in Table I , different mean daily GH secretion rates within and exceeding the approximately physiological range observed in the human across various age spans and body weights yield a correspondingly broad range oftotal, free, and bound GH concentrations in plasma at theoretical equilibrium. Varying the mean secretion rate of GH influences the apparent equilibrium plasma concentrations of free, bound, and total GH, and the percentage occupancy ofthe BP, but less markedly the percentage of GH bound to the BP. The latter decreases slightly (from 39% to 33%) when the mean GH secretion rate is increased 10-fold above the nominal normal value in humans.
Table I also shows the influence of altering the equilibrium dissociation constant. Using the approximate literature value for the equilibrium dissociation constant, namely a kd of 1.5 nM,3 and our measured kff of0.037 /min, we observed that BP affinity for GH influences the total and bound concentrations ofGH in plasma, the percentage ofGH bound, and the percentage occupancy ofthe GH-BP, but not the concentration of free GH. Alternatively, altering the apparent capacity of the BP modifies the concentrations of total and bound GH and percentage of GH bound at any given moment, but does not influence the concentration offree GH or the percentage occupancy of the BP.
The t1/2 of free GH within the physiological range influences the concentrations of free and bound GH in plasma, the t1/2 of total GH, and the percentage of BP that is occupied, but minimally affects the percentage of GH bound; see Table I .
The above results can also be stated in relation to factors that control free, bound, and total GH concentrations, and the percentages of GH bound and of BP occupied in plasma; see Table I . Specifically, the apparent concentration of free GH at equilibrium is controlled positively by the secretion rate and The above computer-simulation data apply to steady-state conditions, which can be achieved by infusions of exogenous GH, but are rarely ifever attained spontaneously under physiological conditions in vivo (30) (31) (32) (33) 35) . A plausible pathological exception at least over short time spans (minutes) may be patients with GH-secreting pituitary tumors, since the latter appear to exhibit intervals of tonic or basal secretion upon which may be superimposed high frequency bursts of GH release (36) . As shown in Fig. 2 , decay from some given steady-state plasma concentration of free, bound, or total GH is influenced by the presence ofa GH-binding element in plasma. The absolute value of the rate constant for an approximated monoexponential decay structure depends upon the amount and binding properties of the GH-BP, the tl/2 of free GH removal, and the starting concentrations of free and bound GH in plasma. For example, for three different starting concentrations oftotal GH in plasma, namely 11, 34, and 101 pM, generated respectively by mean daily secretion rates ofGH of0.1 1, 0.33, and 1.1 mg/24 h (4, 15, and 40 nmol/24 h), we find by monoexponential approximation the apparent t1/2 values shown in Table II .
These values fall within the wide range of measured GH kinetics reported in the available literature (reviewed in references 29 and 33). Fig. 3 gives the monoexponential approximation for bound, total, and free plasma GH half-lives in the presence vs. absence of BP, assuming a range of free GH halflives in the absence ofa BP. Note that a free GH t12 of -7 min in the absence ofBP corresponds to a t,2 of 18 min for total GH when the BP is present in physiological concentrations.
Nonequilibrium conditions. We next simulated the more complex nonequilibrium conditions that are more akin those occurring physiologically. The predicted dynamic effects ofthe BP on the plasma concentrations of free, bound, and total GH over time generated by a secreted pulse ofGH are shown in Fig.  4 . In response to a single pulse of GH, the plasma concentration of free GH increases rapidly, and decays rapidly initially because of removal by irreversible metabolic clearance as well as by association with BP in plasma. The concentration of bound GH increases almost as rapidly, but decays considerably more slowly because molecules of GH dissociate from the BP at a finite rate while some additional molecules ofGH continue to associate with the BP. The plot of total GH concentrations over time is also considerably more extended than the profile of free hormone for the same reason. Of interest, the percentage of GH that is bound to plasma BP begins at -39% (assumed equilibrium approximation of previous secretion events), and declines rapidly as the free GH concentration increases during a pulse ofGH delivery into the bloodstream. The percentage of GH bound to BP then increases over the succeeding minutes, and thereafter begins to fall as GH dissociates from the specific BP reservoir. Table III gives the times to maximal values for free, bound, and total plasma GH concentrations in relation to the three different amounts (nanomoles per burst) of GH injected into the bloodstream. As predicted intuitively, free plasma GH concentration peaks first, followed by the bound and total GH concentrations. We also simulated the effect ofa nearly instantaneous burst of GH into the bloodstream. Here tions in plasma. We used nominal half-lives offree GH of4, 9, 18, and 36 ( Fig. 6 ). The corresponding approximate half-lives of total GH are 16, 21, 37, and 63 min, values which cover the range reported in the literature for physiological and pathological conditions. One-tenth of the daily GH secretion rate was injected as a single pulse in these simulations (22 ,ug or 1 nmol). Note that the times to maximum and the maximal values of the plasma concentrations of free, bound, and total GH are strongly controlled by the apparent half-life offree GH in plasma; see Table III . The pathophysiological impact of decreased plasma GH-BP concentrations on pulsatile free, total, and bound GH concentrations over time is illustrated in Fig. 7 (left panels), which compares GH profiles over 24 h in a normal male (nominal GH-BP concentration 1.0 nM) and a patient with insulin-dependent diabetes mellitus (mean GH-BP concentration 0.725 nM). Nonlinear curve-fitting of the total plasma GH concentrations measured in samples collected at 10-min intervals for 24 h showed significant increases in GH secretion rates and free GH concentrations in diabetes mellitus, and a decrease in total 60 BOUND E ," a/ but not free GH half-life as predicted by the kinetic model. Conversely, the effects of increased serum GH-BP concentrations are shown for comparison in Fig. 7 (right panels), which depicts 24-h serum GH concentration profiles obtained by sampling blood at 10-min intervals for 24 h in an obese middleaged man and a nonobese age-matched control. Assuming a blood GH-BP concentration of 1.7 nM in the obese (vs. 1.0 nM in the normal weight) subject, we used deconvolution analysis to determine the half-life oftotal and free GH, the time-course of plasma GH secretion, and the resultant plasma concentrations of free GH, bound GH, and total GH. The last-mentioned values were compared to measured concentrations of total GH; see Fig. 7 (right panels). The dynamic changes in GH binding over 24 h in the above subjects are illustrated in Fig. 8 . Note that in the healthy, obese, and diabetic men, the percentage ofGH bound to high-affinity BP varies from 10% to 80% over the course of24 h. Ofparticular interest, during intervals of secretory quiescence (i.e., between successive GH secretory bursts), the percentage of GH bound increases progressively, which reflects the reservoir-like and buffering capacity of GH-BP. Conversely, during individual GH secretory bursts, the free concentration of GH increases rapidly and the percentage of bound GH falls with a consequently increased availability of GH to metabolic removal. These dynamics apply to the normal, diabetic, and obese profiles.
Discussion
To evaluate the dynamics ofGH secretion into, removal from, and partitioning within plasma, we formulated a model that assumed either the attainment ofequilibrium plasma GH concentrations (e.g., achieved by constant infusion of exogenous GH, or tonic GH secretion in patients with GH-secreting pitu- Time (min) Figure 6 . Influence ofdifferent free GH half-lives on the profiles of plasma free, bound, and total GH concentrations following a hypothetical GH secretory burst. The hypothetical GH secretory burst with a mass of 1 nmol (22 gg) is described in Fig. 5 (left panels). The four columns of panels depict the anticipated plasma concentrations of free, bound, and total GH assuming monoexponential decay rates of free GH in the absence of BP corresponding to half-lives of 36, 18, 9, or 4 min which correspond to total GH half-lives of 63, 37, 21, and 16 min, respectively.
The last two values bracket the physiological range for published half-lives for total GH in humans.
hormone bound and also the percentage of BP occupied by hormone, the free concentration ofligand at equilibrium is not controlled by the BP affinity. In contrast, the capacity (i.e., concentration) ofthe BP affects the concentration and percentage of hormone bound, but does not modify the steady-state free hormone concentration or the percentage of BP occupied by its ligand. These general inferences apply qualitatively to other ligand-circulating receptor interactions, under similar simplifying assumptions.
If the concentration of free hormone is primarily responsible for hormone action in target tissues, then factors that control the free hormone concentration in plasma are ofparticular interest. We observed that only the secretion rate, t1/2, and VO of the hormone contribute substantially to the equilibrium concentration of free ligand in plasma. BP affinity or capacity do not markedly influence the free hormone concentration at steady state within physiological ranges of hormone secretion rates or half-lives. Indeed, complete absence ofthe BP does not modify the free hormone concentration at steady-state for any given secretion rate. This observation has interesting implications in the interpretation ofhormone concentrations in conditions ofinborn deficiency ofa BP. For example, in Laron dwarfism, there is virtual absence of the GH-BP in plasma, while serum GH concentrations are very high ( 12, 13, 37, 38) . This increase in mean serum GH concentrations indicates mathematically that either the secretion rate and/or the t1/2 ofGH are increased (or the VO for GH is decreased) in Laron dwarfs.
Available data suggest that increased secretion rather than a prolonged t1/2 ofGH occurs in this clinical model ofGH receptor/BP deficiency (39) , in that the predicted (see Fig. 3 ) and measured half-lives ofGH are actually decreased in the absence of BP (17) (18) (19) , and Z. Laron, M. L. Johnson, and J. D. Veldhuis, unpublished data). Such an increase in GH secretion rate presumably results from the failure ofGH-dependent negative feedback mechanisms (such as generation of insulin-like growth factor I, or IGF-I) to suppress GH secretion (40) . Of note, Laron-type dwarfism is not simply a GH-BP deficiency state. The fact that GH receptors are also absent (38, 41 ) is likely to influence free and total GH t112 independently of the BP, as at least part of the clearance of GH proceeds through receptor-mediated internalization into cells and lysosomal degradation. Thus, the combined absence of plasma GH-BP Figure 7 . Dynamic features of GH secretion into free and bound compartments and the resultant effects on total serum GH concentrations (left panels) in a healthy young male (control) and a man with type 1 diabetes mellitus with reduced plasma GH-binding protein concentrations, or (right panels) a middle-aged male control and obese counterpart. Each subject underwent blood sampling at 10-min intervals for 24 h, and the resultant sera were subjected to immunoradiometric assay to estimate total serum GH concentrations (lowermost panels). The GH secretory rate over time was then determined by multiparameter deconvolution analysis (33) (46) . Thus, children with low BP levels tend to have high GH secretion rates, and vice versa. Our computer simulations predict that this physiological relationship in a group of subjects would tend to damp pulsatile free GH availability to target tissues. A buffering effect of constant amounts of high-affinity GH-BP also occurs in individuals over minutes and hours, as shown in Fig. 8 in a normal , diabetic, and obese subjects. In all three conditions, the percentage of GH bound to high-affinity GH-BP varies remarkably over 24 h; viz., from 10% to 80% during the course of minute-to-minute pulsatile GH release (Fig. 8) . Of particular interest, the relative retention of GH in plasma by GH's complexing with BP prevents plasma GH concentrations from falling to zero between successive GH secretory bursts. Indeed, the dissociation rate constant of 0.037/ min equates to a half-life of GH dissociation of 18.7 min, which is considerably longer than our estimated free GH halflife of -7 (2-12) min. Thus, the percentage of GH bound to BP will tend to rise following a secretory burst, as free GH is removed more rapidly than bound. Dissociation of GH from its BP at these times of low or absent GH secretion maintains some free GH in plasma bathing the target tissues, which in circumstances of decreased GH secretion (obesity) may be physiologically relevant. However, whether such low but nonzero concentrations of free GH or GH-BP complex are important in maintaining tissues responsiveness to GH is not known.
Assuming that free hormone is the major (but not necessarily exclusive) moiety subject to irreversible metabolic removal, then differences in the tp12 of free hormone among different individuals will influence the absolute amounts of free and bound GH in plasma, and the percentage occupancy of the GH-BP. Up to fourfold variability has been recognized in the t1/2 of exogenously infused GH, and more recently of endogenously secreted GH in healthy individuals (reviewed in references 29 and 33). Based on Fig. 3 , we therefore can predict free GH half-lives of2-12 min in normal adults. Thus, whether free and/or bound GH acts on target tissues, this variability in GHt,/2 has the potential to modify tissue actions ofGH significantly.
In obese men, the calculated 11/2 ofendogenous GH appears to be somewhat reduced (31 ) . Such calculations assume that the V0 for GH is not significantly increased in obesity. Similarly, in obese orchidectomized Rhesus monkeys, the metabolic clearance rate of human GH infused at a constant rate is significantly higher (47) . A decrease in GHt 1/2 (or increase in metabolic clearance rate) would decrease the amount of free and bound GH bathing target tissues, and thereby contribute to tissue GH deficiency in obesity. Decreased GH 11/2 is not due to evident alterations in BP affinity or capacity, since the estimated serum GH binding capacity is either high-normal or moderately increased in obese men (31, 48) . Thus, alternative mechanisms for the decrease in apparent GH 1/2 in obese individuals should be considered, and might include increased removal ofGH by receptor and/or nonreceptor-mediated mechanisms and/or an increased V0 for GH.
Our measurements of GH-BP concentrations in type I (insulin-dependent) diabetes mellitus reveal a significantly reduced GH-BP capacity (49) . In conjunction with increased GH secretion in type I diabetic patients, the decrease in GH-BP capacity amplifies the already high free GH concentration in plasma and would tend to shorten the half-life oftotal GH (see Fig. 7 , left panels). These observations are consistent with the free GH hypothesis, i.e., metabolic removal of GH proceeds largely or predominantly via free GH rather than by way of complexes of GH-BP.
Our computer simulations also provide a possible basis for interpreting some apparent differences in the reported GHt1/2 in the literature. For example, estimating GH 11/2 before steady state is attained or in response to infusions of pharmacological amounts of GH sufficient to exceed BP capacity would produce a preferential increase in free hormone and yield initial phase kinetic estimates reflecting predominantly the short t1/2 of free hormone. However, measurements of the GH t1/2 within the physiological GH concentration range of50 ng/liter to 50 ,g/L (-2.3 pM to 2.3 nM) would reflect free GHt1/2 only if the laboratory technique did not measure bound hormone-an unlikely possibility in the case of immunoassays (25) . Indeed standard immunochemical assays typically measure total GH in plasma (25) . Thus, the half-lives derived from such measurements reflect the damping effect of the GH-BPs, the concentration of which varies among individuals ( 1 1, 14) . The variability in BP levels may in part explain individual differences in GH clearance. Of course, other factors can introduce variability in estimates of GH 1/2, including measurement technique, assay specificity, buffer and matrix, choice of GH standards, sampling frequency, and the extent to which endogenous GH secretion is suppressed when the t1/2 ofexogenous GH is computed.
The dynamic model of GH secretion and GH partitioning between BP and metabolic clearance presented here can be used to predict the time course ofplasma GH-BP complex and free GH. Although the time course of total, free, and bound GH in blood can be predicted, the exact temporal profiles of free and bound GH to which tissue GH receptors are exposed are not known, since the relative extent to which free GH and GH-BP complex permeate various target tissues has not been defined. An additional unanswered question is: "What timeconfiguration of free GH (or GH-BP complex) in blood most effectively initiates or modifies tissue responses to GH?" For example, under some conditions, a pulsatile rather than a continuous mode of GH delivery preferentially enhances tissue responses, such as linear growth and weight gain in the rat and the induction of epiphyseal cartilage and muscle IGF-I mRNA (50) . In contrast, in acromegaly, the nadir (or mean or integrated) serum GH concentration is the strongest single correlate of serum IGF-I concentrations (36) . Moreover, the induction of a "feminized" pattern of certain hepatic enzymes (e.g., carbonic anhydrase in the rat) is best achieved by continuous GH delivery (51 ) . Near-continuous GH replacement may also be optimal for generating IGF-I in GH-deficient humans (52) .
In conclusion, assuming that plasma GH concentration profiles are transferred to tissue receptor sites, the dynamic interplay among pulsatile GH secretion, intravascular GH partitioning, distribution, high-affinity binding, and irreversible metabolic clearance offers significant regulatory control over tissue GH actions within the somatotropic axis in health and disease.
